Download MendeleyStructure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S).
Shen, J., Zhang, T., Zhu, S.J., Sun, M., Tong, L., Lai, M., Zhang, R., Xu, W., Wu, R., Ding, J., Yun, C.H., Xie, H., Lu, X., Ding, K.(2019) J Med Chem 62: 7302-7308
- PubMed: 31298540
- DOI: https://doi.org/10.1021/acs.jmedchem.9b00576
- Primary Citation of Related Structures:
6JRJ, 6JRK - PubMed Abstract:
Tertiary EGFR C797S mutation induced resistance against osimertinib ( 1 ) is an emerging "unmet clinical need" for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone derivatives were designed and synthesized as new selective EGFR L858R/T790M/C797S inhibitors. A representative compound, 8r-B , exhibited an IC 50 of 27.5 nM against the EGFR L858R/T790M/C797S mutant, while being a significantly less potent for EGFR WT (IC 50 > 1.0 μM). Cocrystallographic structure determination and computational investigation were conducted to elucidate its target selectivity.
Organizational Affiliation:
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy , Jinan University , 601 Huangpu Avenue West , Guangzhou 510632 , China.
